Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
REGULATORY
Alexion’s Voydeya Marks 1st Application of “Early Launch Premium,” but Rate Fully Axed
Alexion Pharmaceuticals’ Voydeya (danicopan) became the first medicine to be eligible for a new “early launch premium” introduced under Japan’s FY2024 drug pricing reform. However, the premium was entirely removed due to its low cost disclosure ratio. Voydeya was among…
To read the full story
Related Article
- MHLW Pharma Management Director Hints at Addressing “Zero” Premium Issue
July 19, 2024
- Rapalimus Granules Now Available in Japan: Nobelpharma
July 9, 2024
- Lilly Rolls Out Eczema Drug Ebglyss in Japan
June 3, 2024
- AnGes to Roll Out Progeria Treatment Zokinvy on May 27
May 24, 2024
- BMS’ Reblozyl Now Available in Japan for Anemia in MDS
May 21, 2024
- Pfizer’s PARP Inhibitor Talzenna Now Available in Japan
April 24, 2024
- Voydeya, High-Dose Eylea, Vyvdura and More Now Available in Japan
April 18, 2024
- Nobelpharma, Argenx Challenged Initial Pricing for New Meds; Claims Partially Accepted
April 11, 2024
- Japan Approves Pfizer’s RSV Jab, Ultragenyx’s Evkeeza, and More
January 19, 2024
REGULATORY
- Another LDP Study Group Submits Emergency Proposal Urging Drug Pricing Overhaul
December 5, 2025
- Ishin Urges Takaichi to Revisit OTC-Like Drug Coverage, Softens Savings Target
December 5, 2025
- JPMA Chief Presses LDP Study Group to Lock In On-Patent Prices, Scrap “Spillover” Rule
December 5, 2025
- LDP, Ishin to Continue OTC-Like Drug Talks on “Special Charge” Design
December 5, 2025
- Forxiga, Zytiga Seen Taking Biggest Hit by PMP Returns in FY2026
December 5, 2025
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…